Hodgkin Lymphoma Clinical Trials in Bologna
13 recruitingBologna, Italy
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Phase 1Phase 2
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
AstraZeneca91 enrolled21 locationsNCT07123454
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca276 enrolled63 locationsNCT06564038
Recruiting
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE
Hodgkin or Non-Hodgkin Lymphoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna60 enrolled2 locationsNCT07313943
Recruiting
Phase 2
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS28 enrolled10 locationsNCT05977673
Recruiting
Phase 1Phase 2
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Hodgkin LymphomaLymphomaNon-Hodgkin
AstraZeneca110 enrolled20 locationsNCT06137144
Recruiting
Not Applicable
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Hodgkin Lymphoma in Remission
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled1 locationNCT06761274
Recruiting
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Hodgkin Lymphoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna40 enrolled1 locationNCT06733987